Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LABP .22 may next AMAM ..this low floater trading way below cash and has a big pipeline
Market Cap $9 mil
Cash balance $48 mil
Huge pipeline
https://landosbiopharma.com/product-candidates/our-pipeline/
(LCI) $0.60 ..Phase 3 data within days ...Market cap $27 million .. there is a potential of 200-300% jump if results are positive
Completed Dosing of Subjects in the Pivotal Biosimilar Insulin Glargine Clinical Trial, Top-line Results Anticipated by Year End; BLA Filing On Track for First Half of 2023
Insider buying
http://openinsider.com/search?q=lci
(ARDS) $0.95 --Phase 3 data in December ...Very low valuation of $22 million ,,positive results could push this stock toward $5
Closed enrollment in the Company’s Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis expects to report top-line data from this study in December 2022.
(ARDS) $0.90 --Phase 3 data in December ...Very low valuation of $22 million ,,positive results could push this stock toward $5
Closed enrollment in the Company’s Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis expects to report top-line data from this study in December 2022.
ARDS $1 --Phase 3 data next week --Market cap $21 million
Closed enrollment in the Company’s Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis expects to report top-line data from this study in December 2022.
(ARDS) $0.90 --Phase 3 data in December ...Very low valuation of $22 million ,,positive results could push this stock toward $5
Closed enrollment in the Company’s Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis expects to report top-line data from this study in December 2022.
(ARDS) $0.90 --Phase 3 data in December ...Very low valuation of $22 million ,,positive results could push this stock toward $5
Closed enrollment in the Company’s Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis expects to report top-line data from this study in December 2022.
LABP $0.23--MC $9 m--Cash $48 m ..dirt cheap biotech with nice pipeline
Pipeline
https://landosbiopharma.com/product-candidates/our-pipeline/
(ARDS) $1.03 --BIG Phase 3 data IMMINENT ...Market cap only $22 million
Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP
expected in December of this year
(ACER) $1.35..FDA Decision next month ..Market cap only $22 million ,,this low floater could run to $2.50-3 ahead of the FDA date
ACER-001 (sodium phenylbutyrate)
The FDA has assigned a new PDUFA target action date of January 15, 2023, on the pending NDA, following the FDA’s acceptance for review of Acer’s resubmitted NDA for ACER-001 for the treatment of patients with UCDs
insider buying
http://openinsider.com/search?q=acer
ACER $1.41 FDA DECISION next month....stock likely to move up in the coming days as we move closer to FDA date
(ACER) $1.30..FDA Decision next month ..Market cap only $21 million ,,this low floater could run to $2.50-3 ahead of the FDA date
ACER-001 (sodium phenylbutyrate)
The FDA has assigned a new PDUFA target action date of January 15, 2023, on the pending NDA, following the FDA’s acceptance for review of Acer’s resubmitted NDA for ACER-001 for the treatment of patients with UCDs
(LCI) $0.59..Phase 3 data imminent ...Market cap $23 million .. there is a potential of 200-300% jump if results are positive
Completed Dosing of Subjects in the Pivotal Biosimilar Insulin Glargine Clinical Trial, Top-line Results Anticipated by Year End; BLA Filing On Track for First Half of 2023
Insider buying
http://openinsider.com/search?q=lci
(LCI) $0.59--Phase 3 data within days ..there are around 4 million shares short so there could be a nice short squeeze on positive results
Completed Dosing of Subjects in the Pivotal Biosimilar Insulin Glargine Clinical Trial, Top-line Results Anticipated by Year End
(LCI) $0.53 ..Phase 3 data imminent ...Market cap $23 million .. there is a potential of 200-300% jump if results are positive
Completed Dosing of Subjects in the Pivotal Biosimilar Insulin Glargine Clinical Trial, Top-line Results Anticipated by Year End; BLA Filing On Track for First Half of 2023
Insider buying
http://openinsider.com/search?q=lci
(ARDS) $0.84 --BIG Phase 3 data in December ...Very low valuation of $17 million ,,positive results could push this stock toward $5
Closed enrollment in the Company’s Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis expects to report top-line data from this study in December 2022.
(DERM) $1.77 --MC $31 m --9x Marketed Drugs + another Drug in ongoing Phase 3 trial with data readout coming in Q2 ...Company trading at Cash balance of $34 million ...
Presentation
https://d1io3yog0oux5.cloudfront.net/_6e68aacef583dd1fa04a3b15d3eca146/journeymedicalcorp/db/2208/19996/pdf/JMC+Company+Overview+-+0422.pdf
(DERM) $1.77 --MC $31 m --9x Marketed Drugs + another Drug in ongoing Phase 3 trial with data readout coming in Q2 ...Company trading at Cash balance of $34 million ...
Presentation
https://d1io3yog0oux5.cloudfront.net/_6e68aacef583dd1fa04a3b15d3eca146/journeymedicalcorp/db/2208/19996/pdf/JMC+Company+Overview+-+0422.pdf
(DERM) $1.84 --MC $32 m --9x Marketed Drugs + another Drug in ongoing Phase 3 trial with data readout coming in Q2 ...Company trading at Cash balance of $34 million ...
Presentation
https://d1io3yog0oux5.cloudfront.net/_6e68aacef583dd1fa04a3b15d3eca146/journeymedicalcorp/db/2208/19996/pdf/JMC+Company+Overview+-+0422.pdf
(CYTH) $1.17 ..MC $9 mil -BIG Phase 3 Drug +Alzheimer treatment in Phase 2 ...likely the most attractive and underpriced biotech of all smallcaps in the sector .
Pipeline
https://cyclotherapeutics.com/pipeline/
Presentation
https://s3.amazonaws.com/b2icontent.irpass.cc/2573/187895.pdf
(FBIO) 0.70 ceo bought 100k shares ...see previous post for more information about the pharma stock
https://www.nasdaq.com/market-activity/stocks/fbio/sec-filings
(FBIO) $0.71 --has 7x PHASE 3 Drugs ---9 Marketed Drugs and around 30 Drugs in early to mid stage ...Market cap only $77 million while Cash balance is at HUGE $248 million...This could be a 5-10 bagger
Check out their presentation
https://d1io3yog0oux5.cloudfront.net/_5c15c03978b625f4b1541ea3d27ec409/fortressbiotech/db/640/5925/pdf/FBIO+Corporate+Presentation+-+Sept+2022.pdf
(DERM) $2.30 -MC $40 m -9 Marketed drugs and more product launches soon , cash balance $38 million and annual revenue to hit $70 million .. under radar stock with massive upside
Presentation
https://d1io3yog0oux5.cloudfront.net/_56df18fb639a06d224aa59b361fc1fb6/journeymedicalcorp/db/2208/19996/pdf/JMC+Company+Overview+-+0422.pdf
(ORTX) MC $58 m..Cash $170 m...company has already an approved drug in europe and they expect to submit BLA for US approval by year end . company trading massive under cash and has strong institutional ownership .this one could double or triple quickly on good news .
https://finance.yahoo.com/news/orchard-therapeutics-reports-second-quarter-110000893.html
Key Upcoming Clinical and Research Milestones ;
OTL-200 for MLD (U.S.): Conduct a pre-Biologics License Application (BLA) meeting with U.S. Food and Drug Administration (FDA) in the second half of 2022 in advance of a BLA submission timeline of late 2022 to early 2023.
OTL-203 for MPS-IH: Initiate a global registrational study in 2023.
OTL-201 for MPS-IIIA: Report clinical data, including early clinical outcomes of cognitive function, from the proof-of-concept (POC) trial by year end 2022.
(DERM) $2.30 -MC $40 m -9 Marketed drugs and more product launches soon , cash balance $38 million and annual revenue to hit $70 million .. under radar stock with massive upside
Presentation
https://d1io3yog0oux5.cloudfront.net/_56df18fb639a06d224aa59b361fc1fb6/journeymedicalcorp/db/2208/19996/pdf/JMC+Company+Overview+-+0422.pdf
(DERM) $2.30 -MC $40 m -9 Marketed drugs and more product launches soon , cash balance $38 million and annual revenue to hit $70 million .. under radar stock with massive upside
Presentation
https://d1io3yog0oux5.cloudfront.net/_56df18fb639a06d224aa59b361fc1fb6/journeymedicalcorp/db/2208/19996/pdf/JMC+Company+Overview+-+0422.pdf
(DERM) $2.35 -MC $40 m -9 Marketed drugs and more product launches soon , cash balance $38 million and annual revenue to hit $70 million .. under radar stock with great upside
Presentation
https://d1io3yog0oux5.cloudfront.net/_56df18fb639a06d224aa59b361fc1fb6/journeymedicalcorp/db/2208/19996/pdf/JMC+Company+Overview+-+0422.pdf
(LIAN) $2 trading 40% under cash and has multiple blockbuster in late stage ..the company largest shareholder Perceptive Advisors bought a lot of shares even above 14 dollars per share ....this is a very attractive buyout target
Insider buying
http://openinsider.com/search?q=lian
https://www.lianbio.com/pipeline/
EYEN $2.20 NEW $12 tgt by Wainwirght
HC Wainwright Starts Eyenovia at Buy With $12 Price Target
10/05/2022 | 07:08am EDT
https://www.marketscreener.com/quote/stock/EYENOVIA-INC-40331595/news/HC-Wainwright-Starts-Eyenovia-at-Buy-With-12-Price-Target-41932504/
(ATHA) $3.05 trading 60% under cash ($6.70 per share) ,has great pipeline and very strong institutional investors ...this stock is a nice reboundplay
Pipeline
https://www.athira.com/pipeline/
Top Institutional Holders
https://www.cnbc.com/quotes/atha?tab=ownership
(DERM) $2.40 ..MC $41 m--9 Marketed Drug another Product to be launched in Q4 + Phase 3 readout in early next year ...Company has annual revenue of more than $70 million ..under radar company with big upside
Presentation
https://d1io3yog0oux5.cloudfront.net/_56df18fb639a06d224aa59b361fc1fb6/journeymedicalcorp/db/2208/19996/pdf/JMC+Company+Overview+-+0422.pdf
World War coming ,,things doesnt look good guys
Ukraine announces fast-track NATO membership bid, rules out Putin talks
https://www.reuters.com/world/europe/zelenskiy-says-ukraine-applying-nato-membership-2022-09-30/
EDSA up 21% ...next milestone is the ACD Phase 2b readout coming within 8 weeks ...
Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study
https://www.streetinsider.com/Accesswire/Edesa+Biotech+Reports+Statistically+Significant+Mortality+Reductions+in+Phase+2+ARDS+Drug+Study/20647965.html